Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-in-human SPECT/CT imaging of [211At]PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer.
Watabe T, Hatano K, Naka S, Sasaki H, Kamiya T, Shirakami Y, Toyoshima A, Cardinale J, Giesel FL, Isohashi K, Nonomura N, Tomiyama N. Watabe T, et al. Among authors: toyoshima a. Eur J Nucl Med Mol Imaging. 2024 Dec 17. doi: 10.1007/s00259-024-07017-w. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 39688698 No abstract available.
Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound.
Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Ooe K, Wang Y, Haba H, Toyoshima A, Cardinale J, Giesel FL, Tomiyama N, Fukase K. Watabe T, et al. Among authors: toyoshima a. Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):849-858. doi: 10.1007/s00259-022-06016-z. Epub 2022 Nov 8. Eur J Nucl Med Mol Imaging. 2023. PMID: 36344651 Free PMC article.
Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.
Watabe T, Kabayama K, Naka S, Yamamoto R, Kaneda K, Serada S, Ooe K, Toyoshima A, Wang Y, Haba H, Kurimoto K, Kobayashi T, Shimosegawa E, Tomiyama N, Fukase K, Naka T. Watabe T, et al. Among authors: toyoshima a. J Nucl Med. 2023 Dec 1;64(12):1949-1955. doi: 10.2967/jnumed.123.266313. J Nucl Med. 2023. PMID: 37827841 Free PMC article.
Preclinical Evaluation of Biodistribution and Toxicity of [211At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer.
Watabe T, Kaneda-Nakashima K, Kadonaga Y, Ooe K, Sampunta T, Hirose N, Yin X, Haba H, Kon Y, Toyoshima A, Cardinale J, Giesel FL, Fukase K, Tomiyama N, Shirakami Y. Watabe T, et al. Among authors: toyoshima a. Int J Mol Sci. 2024 May 23;25(11):5667. doi: 10.3390/ijms25115667. Int J Mol Sci. 2024. PMID: 38891856 Free PMC article.
Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models.
Abe K, Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Naka S, Ooe K, Toyoshima A, Giesel F, Usui T, Masunaga N, Mishima C, Tsukabe M, Yoshinami T, Sota Y, Miyake T, Tanei T, Shimoda M, Shimazu K. Abe K, et al. Among authors: toyoshima a. Int J Mol Sci. 2024 Oct 28;25(21):11567. doi: 10.3390/ijms252111567. Int J Mol Sci. 2024. PMID: 39519118 Free PMC article.
Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.
Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Watabe T, Ooe K, Yin X, Haba H, Shirasaki K, Kikunaga H, Tsukada K, Toyoshima A, Cardinale J, Giesel FL, Fukase K. Kaneda-Nakashima K, et al. Among authors: toyoshima a. Int J Mol Sci. 2024 Jan 11;25(2):933. doi: 10.3390/ijms25020933. Int J Mol Sci. 2024. PMID: 38256007 Free PMC article.
130 results